Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
Background: Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). Due to their specific actions, these kinds of interventions will only be effective in particular subsets of patients. To anticipa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central Ltd
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |